These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23 related articles for article (PubMed ID: 80708)
1. Dopamine agonists and analogues have an antiproliferative effect on CHO-K1 cells. Maggio R; Armogida M; Scarselli M; Salvadori F; Longoni B; Pardini C; Chiarenza A; Chiacchio S; Vaglini F; Bernardini R; Colzi A; Corsini GU Neurotox Res; 2000 Apr; 1(4):285-97. PubMed ID: 12835096 [TBL] [Abstract][Full Text] [Related]
2. Hyperprolactinaemia--investigation and results of treatment. Wilson JD; Boyle DD; Harley JM; Montgomery DA; Sheridan B Ulster Med J; 1980; 49(1):85-98. PubMed ID: 7394929 [No Abstract] [Full Text] [Related]
3. Bromocriptine treatment of macroprolactinomas: studies on the time course of tumor shrinkage and morphology. Nissim M; Ambrosi B; Bernasconi V; Giannattasio G; Giovanelli MA; Bassetti M; Vaccari U; Moriondo P; Spada A; Travaglini P; Faglia G J Endocrinol Invest; 1982; 5(6):409-15. PubMed ID: 7169515 [No Abstract] [Full Text] [Related]
5. The 'Alice in Wonderland' experience. Ergot alkaloid therapy for prolactin-secreting pituitary tumors. Williams RC; Sherman C; Buckman MT West J Med; 1983 Mar; 138(3):391-7. PubMed ID: 6858128 [TBL] [Abstract][Full Text] [Related]
6. The endocrine profile of bromocriptine: its application in endocrine diseases. Lancranjan I J Neural Transm; 1981; 51(1-2):61-82. PubMed ID: 6455501 [TBL] [Abstract][Full Text] [Related]
7. Some current aspects of clinical and experimental neuroendocrinology with particular reference to growth hormone, thyrotropin and prolactin. Scanlon MF; Pourmand M; McGregor AM; Rodriguez-Arnao MD; Hall K; Gomez-Pan A; Hall R J Endocrinol Invest; 1979; 2(3):307-31. PubMed ID: 231066 [No Abstract] [Full Text] [Related]
8. Pituitary adenomas. An update on their management with an emphasis on the role of bromocriptine. Barrow DL; Tindall GT J Clin Neuroophthalmol; 1983 Dec; 3(4):229-37. PubMed ID: 6232287 [TBL] [Abstract][Full Text] [Related]
9. Bromocriptine in pituitary tumours. Corenblum B Lancet; 1978 Oct; 2(8093):786. PubMed ID: 80708 [No Abstract] [Full Text] [Related]
10. Bromocriptine and pituitary disorders. Kellett J; Friesen HG Ann Intern Med; 1979 Jun; 90(6):980-2. PubMed ID: 443696 [No Abstract] [Full Text] [Related]
11. Regression of pituitary prolactinoma after treatment with bromocriptine. Landolt AM; Wüthrich R; Fellmann H Lancet; 1979 May; 1(8125):1082-3. PubMed ID: 86800 [No Abstract] [Full Text] [Related]
12. Hyperprolactinemia. Morphologic and clinical considerations. Ezrin C; Kovacs K; Horvath E Med Clin North Am; 1978 Mar; 62(2):393-408. PubMed ID: 205742 [No Abstract] [Full Text] [Related]
13. Suppression of prolactin macroadenoma in 8 weeks with bromocriptine. Pulinx EM; Claeys L; Liesenborghs L Acta Clin Belg; 1981; 36(4):217-8. PubMed ID: 7315128 [No Abstract] [Full Text] [Related]
14. Bromocriptine reduces the size of cells in prolactin-secreting pituitary adenomas. Landolt AM; Minder H; Osterwalder V; Landolt TA Experientia; 1983 Jun; 39(6):625-6. PubMed ID: 6852202 [TBL] [Abstract][Full Text] [Related]